AFFILIATIONS
1 Case Western Reserve University, Cleveland, Ohio, United States
2 Case Western Reserve University, Cleveland, Ohio, United States
ABSTRACT
Background: Sickle cell disease (SCD) affects over 7 million people worldwide, with more than 100 million carrying trait-associated risks, underscoring the need for scalable therapies that directly target hemoglobin S (HbS) polymerization. The β6 Glu→Val substitution creates hydrophobic surfaces that drive polymer formation upon deoxygenation, producing the rigid fibers responsible for sickled red blood cell (RBC) morphology. A therapeutic that directly engages and modifies polymer-driving interactions on the HbS interface is central to targeting SCD.
To address this, we previously developed an RNA aptamers, DE3A, that bind to HbS and reduce polymerization under deoxygenated conditions. Building on this work, we showed that a truncated variant of DE3A, DE3At, can enter erythroid cells and reduce sickling, consistent with intracellular inhibition of polymer formation. To elucidate a plausible uptake route, we investigated the transferrin receptor (CD71) mediated pathway, as it is highly expressed on erythroid precursors and sickled RBCs. Here we present a mechanistic framework for receptor-mediated transport of DE3At and its direct engagement with intracellular HbS, defining how the aptamer accesses and modifies the polymer-driving interface to contribute to its anti-sickling activity.
Methods: EMSA was performed to evaluate dose-dependent DE3At binding to CD71 and hemoglobin variants (HbA, HbS, HbF). In silico modeling using deoxygenated HbS crystal structures defined the predicted DE3At interface interactions.
Immortalized human umbilical cord blood-derived erythroid progenitor cells genetically engineered to produce sickle β-globin (sHUDEP-2) were used in this study. To assess receptor-associated uptake, HUDEP-2 and sHUDEP-2 cells were incubated with dual-labeled DE3At, containing a pH-sensitive FAM fluorophore at the 5’ end and a pH-insensitive Cy5 reference dye at the 3’ end. CD71 was counterstained with Alexa 568. Cells were imaged over 4 hours, and ratiometric FAM/Cy5 values were quantified to track endosomal progress using ImageJ.
Using the same ratiometric system and imaging conditions described above, we separately examined colocalization with intracellular hemoglobin, counterstained with Alexa 568.
Results: EMSA confirmed dose-dependent complex formation between DE3At and CD71. It was also shown that DE3At formed dose-dependent complexes with HbA and HbS but no detectable interaction with HbF, indicating selectivity for the α/β-globin interface. In HbS, increasing aptamer concentrations preferentially shifted to a higher-order species, suggesting recognition of an HbS-specific conformational or oligomeric state.
DE3At displayed a stepwise intracellular pattern beginning with strong FAM signal and high colocalization with CD71, indicating some initial residence in a more acidic compartment associated with receptor uptake. Subsequently, there was an increased FAM/Cy5 overlap that produced a yellow signal corresponding to a more neutral pH, consistent with cytosolic release. Hemoglobin colocalization increased only after this shift toward a neutral pH, peaking after cytosolic release. Together, these observations suggest that DE3At associates with CD71 during early uptake and transitions to cytosolic release, ultimately engaging intracellular hemoglobin.
Supporting the EMSA results, in silico modeling placed DE3At at the β1/α2 interface adjacent to the hydrophobic β6 patch and on the opposing side of the polymer-stabilizing interface. This orientation suggests that DE3At may weaken polymer-stabilizing contacts allosterically while its unbound portion imposes steric hindrance that limits access of a secondary HbS monomer to the hydrophobic pocket. Ongoing MD simulations are refining this model and will further define how DE3At influences polymer-driving interactions.
Conclusion: DE3At is independently internalized by erythroid cells, traffics through CD71-associated endosomal pathways, escapes into the cytosol, and directly engages HbS. By modifying polymer-driving interactions on the HbS surface, DE3At reduces polymer formation and delays sickling, establishing an RNA-based therapeutic strategy that targets the molecular root of SCD.
DISCLOSURES
Alicia Matthews, N/A: No relevant conflicts of interest to declare.